PDL BioPharma to Exchange Approximately 80% of Convertible Notes Due 2021 and 2024
INCLINE VILLAGE, Nev., Dec. 13, 2019 |PRNewswire| -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has entered into separate, privately negotiated exchange agreements pursuant to which it will exchange $119.3 million in aggregate principal amount of…
PDL BioPharma to Exchange Approximately 80% of Convertible Notes Due 2021 and 2024
INCLINE VILLAGE, Nev., Dec. 13, 2019 |PRNewswire| -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has entered into separate, privately negotiated exchange agreements pursuant to which it will exchange $119.3 million in aggregate principal amount of…